Global CAR T-Cell Immunotherapy Market by Application (Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia), by Target Antigen (CD19, CD22), by End User (Diagnostic Center, Hospital), by Product (Autologous CAR T-Cells, Allogeneic CAR T-Cells) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “CAR T-Cell Immunotherapy Market research report which is segmented by Application (Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia), by Target Antigen (CD19, CD22), by End User (Diagnostic Center, Hospital), by Product (Autologous CAR T-Cells, Allogeneic CAR T-Cells), By Players/Companies Carina Biotech, Atara Biotherapeutics, Pfizer, Juno Therapeutics, Kite Pharma, Sorrento Therapeutics, Cellectis, Legend Biotech, Bristol Myers Squibb, Novartis, CARSGEN Therapeutics Ltd., Guangzhou Xiangxue Pharmaceutical”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | CAR T-Cell Immunotherapy Market Research Report |
| By Application | Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia |
| By Target Antigen | CD19, CD22 |
| By End User | Diagnostic Center, Hospital |
| By Product | Autologous CAR T-Cells, Allogeneic CAR T-Cells |
| By Companies | Carina Biotech, Atara Biotherapeutics, Pfizer, Juno Therapeutics, Kite Pharma, Sorrento Therapeutics, Cellectis, Legend Biotech, Bristol Myers Squibb, Novartis, CARSGEN Therapeutics Ltd., Guangzhou Xiangxue Pharmaceutical |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 201 |
| Number of Tables & Figures | 141 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global CAR T-Cell Immunotherapy Market Report Segments:
The market is segmented by Application (Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia), by Target Antigen (CD19, CD22), by End User (Diagnostic Center, Hospital), by Product (Autologous CAR T-Cells, Allogeneic CAR T-Cells).
CAR T-Cell Immunotherapy Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the CAR T-Cell Immunotherapy Market
Overview of the regional outlook of the CAR T-Cell Immunotherapy Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The CAR T-Cell Immunotherapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of CAR T-Cell Immunotherapy Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Diffuse Large B-cell Lymphoma
2. Acute Lymphoblastic Leukemia
7. By Target Antigen:1. CD19
2. CD22
8. By End User:1. Diagnostic Center
2. Hospital
9. By Product:1. Autologous CAR T-Cells
2. Allogeneic CAR T-Cells
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CAR T-Cell Immunotherapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the CAR T-Cell Immunotherapy Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CAR T-Cell Immunotherapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CAR T-Cell Immunotherapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CAR T-Cell Immunotherapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CAR T-Cell Immunotherapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CAR T-Cell Immunotherapy Market Size & Forecast, 2018-2028
4.5.1 CAR T-Cell Immunotherapy Market Size and Y-o-Y Growth
4.5.2 CAR T-Cell Immunotherapy Market Absolute $ Opportunity
Chapter 5 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Application
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Application
5.1.2 Basis Point Share (BPS) Analysis by Application
5.1.3 Absolute $ Opportunity Assessment by Application
5.2 CAR T-Cell Immunotherapy Market Size Forecast by Application
5.2.1 Diffuse Large B-cell Lymphoma
5.2.2 Acute Lymphoblastic Leukemia
5.3 Market Attractiveness Analysis by Application
Chapter 6 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Target Antigen
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Target Antigen
6.1.2 Basis Point Share (BPS) Analysis by Target Antigen
6.1.3 Absolute $ Opportunity Assessment by Target Antigen
6.2 CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
6.2.1 CD19
6.2.2 CD22
6.3 Market Attractiveness Analysis by Target Antigen
Chapter 7 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by End User
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by End User
7.1.2 Basis Point Share (BPS) Analysis by End User
7.1.3 Absolute $ Opportunity Assessment by End User
7.2 CAR T-Cell Immunotherapy Market Size Forecast by End User
7.2.1 Diagnostic Center
7.2.2 Hospital
7.3 Market Attractiveness Analysis by End User
Chapter 8 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Product
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Product
8.1.2 Basis Point Share (BPS) Analysis by Product
8.1.3 Absolute $ Opportunity Assessment by Product
8.2 CAR T-Cell Immunotherapy Market Size Forecast by Product
8.2.1 Autologous CAR T-Cells
8.2.2 Allogeneic CAR T-Cells
8.3 Market Attractiveness Analysis by Product
Chapter 9 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 CAR T-Cell Immunotherapy Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America CAR T-Cell Immunotherapy Analysis and Forecast
11.1 Introduction
11.2 North America CAR T-Cell Immunotherapy Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America CAR T-Cell Immunotherapy Market Size Forecast by Application
11.6.1 Diffuse Large B-cell Lymphoma
11.6.2 Acute Lymphoblastic Leukemia
11.7 Basis Point Share (BPS) Analysis by Application
11.8 Absolute $ Opportunity Assessment by Application
11.9 Market Attractiveness Analysis by Application
11.10 North America CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
11.10.1 CD19
11.10.2 CD22
11.11 Basis Point Share (BPS) Analysis by Target Antigen
11.12 Absolute $ Opportunity Assessment by Target Antigen
11.13 Market Attractiveness Analysis by Target Antigen
11.14 North America CAR T-Cell Immunotherapy Market Size Forecast by End User
11.14.1 Diagnostic Center
11.14.2 Hospital
11.15 Basis Point Share (BPS) Analysis by End User
11.16 Absolute $ Opportunity Assessment by End User
11.17 Market Attractiveness Analysis by End User
11.18 North America CAR T-Cell Immunotherapy Market Size Forecast by Product
11.18.1 Autologous CAR T-Cells
11.18.2 Allogeneic CAR T-Cells
11.19 Basis Point Share (BPS) Analysis by Product
11.20 Absolute $ Opportunity Assessment by Product
11.21 Market Attractiveness Analysis by Product
Chapter 12 Europe CAR T-Cell Immunotherapy Analysis and Forecast
12.1 Introduction
12.2 Europe CAR T-Cell Immunotherapy Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe CAR T-Cell Immunotherapy Market Size Forecast by Application
12.6.1 Diffuse Large B-cell Lymphoma
12.6.2 Acute Lymphoblastic Leukemia
12.7 Basis Point Share (BPS) Analysis by Application
12.8 Absolute $ Opportunity Assessment by Application
12.9 Market Attractiveness Analysis by Application
12.10 Europe CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
12.10.1 CD19
12.10.2 CD22
12.11 Basis Point Share (BPS) Analysis by Target Antigen
12.12 Absolute $ Opportunity Assessment by Target Antigen
12.13 Market Attractiveness Analysis by Target Antigen
12.14 Europe CAR T-Cell Immunotherapy Market Size Forecast by End User
12.14.1 Diagnostic Center
12.14.2 Hospital
12.15 Basis Point Share (BPS) Analysis by End User
12.16 Absolute $ Opportunity Assessment by End User
12.17 Market Attractiveness Analysis by End User
12.18 Europe CAR T-Cell Immunotherapy Market Size Forecast by Product
12.18.1 Autologous CAR T-Cells
12.18.2 Allogeneic CAR T-Cells
12.19 Basis Point Share (BPS) Analysis by Product
12.20 Absolute $ Opportunity Assessment by Product
12.21 Market Attractiveness Analysis by Product
Chapter 13 Asia Pacific CAR T-Cell Immunotherapy Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Application
13.6.1 Diffuse Large B-cell Lymphoma
13.6.2 Acute Lymphoblastic Leukemia
13.7 Basis Point Share (BPS) Analysis by Application
13.8 Absolute $ Opportunity Assessment by Application
13.9 Market Attractiveness Analysis by Application
13.10 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
13.10.1 CD19
13.10.2 CD22
13.11 Basis Point Share (BPS) Analysis by Target Antigen
13.12 Absolute $ Opportunity Assessment by Target Antigen
13.13 Market Attractiveness Analysis by Target Antigen
13.14 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by End User
13.14.1 Diagnostic Center
13.14.2 Hospital
13.15 Basis Point Share (BPS) Analysis by End User
13.16 Absolute $ Opportunity Assessment by End User
13.17 Market Attractiveness Analysis by End User
13.18 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Product
13.18.1 Autologous CAR T-Cells
13.18.2 Allogeneic CAR T-Cells
13.19 Basis Point Share (BPS) Analysis by Product
13.20 Absolute $ Opportunity Assessment by Product
13.21 Market Attractiveness Analysis by Product
Chapter 14 Latin America CAR T-Cell Immunotherapy Analysis and Forecast
14.1 Introduction
14.2 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Application
14.6.1 Diffuse Large B-cell Lymphoma
14.6.2 Acute Lymphoblastic Leukemia
14.7 Basis Point Share (BPS) Analysis by Application
14.8 Absolute $ Opportunity Assessment by Application
14.9 Market Attractiveness Analysis by Application
14.10 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
14.10.1 CD19
14.10.2 CD22
14.11 Basis Point Share (BPS) Analysis by Target Antigen
14.12 Absolute $ Opportunity Assessment by Target Antigen
14.13 Market Attractiveness Analysis by Target Antigen
14.14 Latin America CAR T-Cell Immunotherapy Market Size Forecast by End User
14.14.1 Diagnostic Center
14.14.2 Hospital
14.15 Basis Point Share (BPS) Analysis by End User
14.16 Absolute $ Opportunity Assessment by End User
14.17 Market Attractiveness Analysis by End User
14.18 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Product
14.18.1 Autologous CAR T-Cells
14.18.2 Allogeneic CAR T-Cells
14.19 Basis Point Share (BPS) Analysis by Product
14.20 Absolute $ Opportunity Assessment by Product
14.21 Market Attractiveness Analysis by Product
Chapter 15 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Application
15.6.1 Diffuse Large B-cell Lymphoma
15.6.2 Acute Lymphoblastic Leukemia
15.7 Basis Point Share (BPS) Analysis by Application
15.8 Absolute $ Opportunity Assessment by Application
15.9 Market Attractiveness Analysis by Application
15.10 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
15.10.1 CD19
15.10.2 CD22
15.11 Basis Point Share (BPS) Analysis by Target Antigen
15.12 Absolute $ Opportunity Assessment by Target Antigen
15.13 Market Attractiveness Analysis by Target Antigen
15.14 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by End User
15.14.1 Diagnostic Center
15.14.2 Hospital
15.15 Basis Point Share (BPS) Analysis by End User
15.16 Absolute $ Opportunity Assessment by End User
15.17 Market Attractiveness Analysis by End User
15.18 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Product
15.18.1 Autologous CAR T-Cells
15.18.2 Allogeneic CAR T-Cells
15.19 Basis Point Share (BPS) Analysis by Product
15.20 Absolute $ Opportunity Assessment by Product
15.21 Market Attractiveness Analysis by Product
Chapter 16 Competition Landscape
16.1 CAR T-Cell Immunotherapy Market: Competitive Dashboard
16.2 Global CAR T-Cell Immunotherapy Market: Market Share Analysis, 2019
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 Carina Biotech
16.3.2 Atara Biotherapeutics
16.3.3 Pfizer
16.3.4 Juno Therapeutics
16.3.5 Kite Pharma
16.3.6 Sorrento Therapeutics
16.3.7 Cellectis
16.3.8 Legend Biotech
16.3.9 Bristol Myers Squibb
16.3.10 Novartis
16.3.11 CARSGEN Therapeutics Ltd.
16.3.12 Guangzhou Xiangxue Pharmaceutical
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CAR T-Cell Immunotherapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CAR T-Cell Immunotherapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CAR T-Cell Immunotherapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CAR T-Cell Immunotherapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CAR T-Cell Immunotherapy Market Size & Forecast, 2018-2028
4.5.1 CAR T-Cell Immunotherapy Market Size and Y-o-Y Growth
4.5.2 CAR T-Cell Immunotherapy Market Absolute $ Opportunity
Chapter 5 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Application
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Application
5.1.2 Basis Point Share (BPS) Analysis by Application
5.1.3 Absolute $ Opportunity Assessment by Application
5.2 CAR T-Cell Immunotherapy Market Size Forecast by Application
5.2.1 Diffuse Large B-cell Lymphoma
5.2.2 Acute Lymphoblastic Leukemia
5.3 Market Attractiveness Analysis by Application
Chapter 6 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Target Antigen
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Target Antigen
6.1.2 Basis Point Share (BPS) Analysis by Target Antigen
6.1.3 Absolute $ Opportunity Assessment by Target Antigen
6.2 CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
6.2.1 CD19
6.2.2 CD22
6.3 Market Attractiveness Analysis by Target Antigen
Chapter 7 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by End User
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by End User
7.1.2 Basis Point Share (BPS) Analysis by End User
7.1.3 Absolute $ Opportunity Assessment by End User
7.2 CAR T-Cell Immunotherapy Market Size Forecast by End User
7.2.1 Diagnostic Center
7.2.2 Hospital
7.3 Market Attractiveness Analysis by End User
Chapter 8 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Product
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Product
8.1.2 Basis Point Share (BPS) Analysis by Product
8.1.3 Absolute $ Opportunity Assessment by Product
8.2 CAR T-Cell Immunotherapy Market Size Forecast by Product
8.2.1 Autologous CAR T-Cells
8.2.2 Allogeneic CAR T-Cells
8.3 Market Attractiveness Analysis by Product
Chapter 9 Global CAR T-Cell Immunotherapy Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 CAR T-Cell Immunotherapy Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America CAR T-Cell Immunotherapy Analysis and Forecast
11.1 Introduction
11.2 North America CAR T-Cell Immunotherapy Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America CAR T-Cell Immunotherapy Market Size Forecast by Application
11.6.1 Diffuse Large B-cell Lymphoma
11.6.2 Acute Lymphoblastic Leukemia
11.7 Basis Point Share (BPS) Analysis by Application
11.8 Absolute $ Opportunity Assessment by Application
11.9 Market Attractiveness Analysis by Application
11.10 North America CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
11.10.1 CD19
11.10.2 CD22
11.11 Basis Point Share (BPS) Analysis by Target Antigen
11.12 Absolute $ Opportunity Assessment by Target Antigen
11.13 Market Attractiveness Analysis by Target Antigen
11.14 North America CAR T-Cell Immunotherapy Market Size Forecast by End User
11.14.1 Diagnostic Center
11.14.2 Hospital
11.15 Basis Point Share (BPS) Analysis by End User
11.16 Absolute $ Opportunity Assessment by End User
11.17 Market Attractiveness Analysis by End User
11.18 North America CAR T-Cell Immunotherapy Market Size Forecast by Product
11.18.1 Autologous CAR T-Cells
11.18.2 Allogeneic CAR T-Cells
11.19 Basis Point Share (BPS) Analysis by Product
11.20 Absolute $ Opportunity Assessment by Product
11.21 Market Attractiveness Analysis by Product
Chapter 12 Europe CAR T-Cell Immunotherapy Analysis and Forecast
12.1 Introduction
12.2 Europe CAR T-Cell Immunotherapy Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe CAR T-Cell Immunotherapy Market Size Forecast by Application
12.6.1 Diffuse Large B-cell Lymphoma
12.6.2 Acute Lymphoblastic Leukemia
12.7 Basis Point Share (BPS) Analysis by Application
12.8 Absolute $ Opportunity Assessment by Application
12.9 Market Attractiveness Analysis by Application
12.10 Europe CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
12.10.1 CD19
12.10.2 CD22
12.11 Basis Point Share (BPS) Analysis by Target Antigen
12.12 Absolute $ Opportunity Assessment by Target Antigen
12.13 Market Attractiveness Analysis by Target Antigen
12.14 Europe CAR T-Cell Immunotherapy Market Size Forecast by End User
12.14.1 Diagnostic Center
12.14.2 Hospital
12.15 Basis Point Share (BPS) Analysis by End User
12.16 Absolute $ Opportunity Assessment by End User
12.17 Market Attractiveness Analysis by End User
12.18 Europe CAR T-Cell Immunotherapy Market Size Forecast by Product
12.18.1 Autologous CAR T-Cells
12.18.2 Allogeneic CAR T-Cells
12.19 Basis Point Share (BPS) Analysis by Product
12.20 Absolute $ Opportunity Assessment by Product
12.21 Market Attractiveness Analysis by Product
Chapter 13 Asia Pacific CAR T-Cell Immunotherapy Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Application
13.6.1 Diffuse Large B-cell Lymphoma
13.6.2 Acute Lymphoblastic Leukemia
13.7 Basis Point Share (BPS) Analysis by Application
13.8 Absolute $ Opportunity Assessment by Application
13.9 Market Attractiveness Analysis by Application
13.10 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
13.10.1 CD19
13.10.2 CD22
13.11 Basis Point Share (BPS) Analysis by Target Antigen
13.12 Absolute $ Opportunity Assessment by Target Antigen
13.13 Market Attractiveness Analysis by Target Antigen
13.14 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by End User
13.14.1 Diagnostic Center
13.14.2 Hospital
13.15 Basis Point Share (BPS) Analysis by End User
13.16 Absolute $ Opportunity Assessment by End User
13.17 Market Attractiveness Analysis by End User
13.18 Asia Pacific CAR T-Cell Immunotherapy Market Size Forecast by Product
13.18.1 Autologous CAR T-Cells
13.18.2 Allogeneic CAR T-Cells
13.19 Basis Point Share (BPS) Analysis by Product
13.20 Absolute $ Opportunity Assessment by Product
13.21 Market Attractiveness Analysis by Product
Chapter 14 Latin America CAR T-Cell Immunotherapy Analysis and Forecast
14.1 Introduction
14.2 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Application
14.6.1 Diffuse Large B-cell Lymphoma
14.6.2 Acute Lymphoblastic Leukemia
14.7 Basis Point Share (BPS) Analysis by Application
14.8 Absolute $ Opportunity Assessment by Application
14.9 Market Attractiveness Analysis by Application
14.10 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
14.10.1 CD19
14.10.2 CD22
14.11 Basis Point Share (BPS) Analysis by Target Antigen
14.12 Absolute $ Opportunity Assessment by Target Antigen
14.13 Market Attractiveness Analysis by Target Antigen
14.14 Latin America CAR T-Cell Immunotherapy Market Size Forecast by End User
14.14.1 Diagnostic Center
14.14.2 Hospital
14.15 Basis Point Share (BPS) Analysis by End User
14.16 Absolute $ Opportunity Assessment by End User
14.17 Market Attractiveness Analysis by End User
14.18 Latin America CAR T-Cell Immunotherapy Market Size Forecast by Product
14.18.1 Autologous CAR T-Cells
14.18.2 Allogeneic CAR T-Cells
14.19 Basis Point Share (BPS) Analysis by Product
14.20 Absolute $ Opportunity Assessment by Product
14.21 Market Attractiveness Analysis by Product
Chapter 15 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Application
15.6.1 Diffuse Large B-cell Lymphoma
15.6.2 Acute Lymphoblastic Leukemia
15.7 Basis Point Share (BPS) Analysis by Application
15.8 Absolute $ Opportunity Assessment by Application
15.9 Market Attractiveness Analysis by Application
15.10 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Target Antigen
15.10.1 CD19
15.10.2 CD22
15.11 Basis Point Share (BPS) Analysis by Target Antigen
15.12 Absolute $ Opportunity Assessment by Target Antigen
15.13 Market Attractiveness Analysis by Target Antigen
15.14 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by End User
15.14.1 Diagnostic Center
15.14.2 Hospital
15.15 Basis Point Share (BPS) Analysis by End User
15.16 Absolute $ Opportunity Assessment by End User
15.17 Market Attractiveness Analysis by End User
15.18 Middle East & Africa (MEA) CAR T-Cell Immunotherapy Market Size Forecast by Product
15.18.1 Autologous CAR T-Cells
15.18.2 Allogeneic CAR T-Cells
15.19 Basis Point Share (BPS) Analysis by Product
15.20 Absolute $ Opportunity Assessment by Product
15.21 Market Attractiveness Analysis by Product
Chapter 16 Competition Landscape
16.1 CAR T-Cell Immunotherapy Market: Competitive Dashboard
16.2 Global CAR T-Cell Immunotherapy Market: Market Share Analysis, 2019
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 Carina Biotech
16.3.2 Atara Biotherapeutics
16.3.3 Pfizer
16.3.4 Juno Therapeutics
16.3.5 Kite Pharma
16.3.6 Sorrento Therapeutics
16.3.7 Cellectis
16.3.8 Legend Biotech
16.3.9 Bristol Myers Squibb
16.3.10 Novartis
16.3.11 CARSGEN Therapeutics Ltd.
16.3.12 Guangzhou Xiangxue Pharmaceutical
Segments Covered in the Report
The global CAR T-Cell Immunotherapy market has been segmented based on
By Application
The global CAR T-Cell Immunotherapy market has been segmented based on
By Application
- Diffuse Large B-cell Lymphoma
- Acute Lymphoblastic Leukemia
- CD19
- CD22
- Diagnostic Center
- Hospital
- Autologous CAR T-Cells
- Allogeneic CAR T-Cells
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Carina Biotech
- Atara Biotherapeutics
- Pfizer
- Juno Therapeutics
- Kite Pharma
- Sorrento Therapeutics
- Cellectis
- Legend Biotech
- Bristol Myers Squibb
- Novartis
- CARSGEN Therapeutics Ltd.
- Guangzhou Xiangxue Pharmaceutical
Our Clients
Related Reports
Some other reports from this category!
